| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.07. | Grifols SA - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 30.07. | GRIFOLS, S.A.: Changes in the Board of Directors. | 9 | CNMV | ||
| GRIFOLS SA ADR 1/2/EO Aktie jetzt für 0€ handeln | |||||
| 29.07. | FOXO unit to acquire four U.S. blood collection centers from Grifols subsidiary | 8 | Seeking Alpha | ||
| 29.07. | Ibex 35 closes flat, stocks hit hard in recent months - Amadeus, Cellnex and Grifols - stand out | 6 | thecorner.eu | ||
| 28.07. | Grifols H1 2026 slides: cash flow surges as IG drives growth | 14 | Investing.com | ||
| 28.07. | Grifols H1 Profit Rises 29%; Backs FY26 Outlook | 563 | AFX News | MADRID (dpa-AFX) - Grifols S.A. (GRFS) on Tuesday reported higher profit for the first half of 2026, supported by growth in its Biopharma business. The company also reaffirmed its full-year... ► Artikel lesen | |
| 28.07. | GRIFOLS, S.A.: Grifols releases financial information for the second quarter of 2026 | 12 | CNMV | ||
| 27.07. | Grifols S.A. Q2 2026 Earnings Preview | 23 | Seeking Alpha | ||
| 16.07. | Grifols doses first patients in two phase 3 immunoglobulin trials | 3 | Investing.com | ||
| 16.07. | Grifols, S.A.: Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins | 403 | GlobeNewswire (Europe) | One trial, SIGMA, will evaluate Grifols' intravenous immunoglobulin (Ig) GAMUNEX- -C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients... ► Artikel lesen | |
| 03.07. | Grifols adopts dual operating model, separating US plasma division from rest of global structure | 32 | thecorner.eu | ||
| 02.07. | Dividendenbekanntmachungen (02.07.2026) | 14.522 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABM INDUSTRIES INC US0009571003 0,29 USD 0,2548 EUR ACME UNITED CORPORATION US0048161048 0,16 USD 0,1406 EUR AGF MANAGEMENT LIMITED CA0010921058 0... ► Artikel lesen | |
| 26.06. | Grifols, Walt Disney, Mondelez und mehr Dividenden im global market - Ex-Tag 30.06.2026 | 16 | Wiener Börse | ||
| 22.06. | GRIFOLS, S.A.: Changes in the Board of Directors. | 19 | CNMV | ||
| 19.06. | Grifols (GRFS) Launches FESILTY in the U.S. for Congenital Fibrinogen Deficiency Treatment | 10 | Insider Monkey | ||
| 18.06. | Grifols SA - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 18.06. | GRIFOLS, S.A.: Ordinary General Shareholders' Meeting 2026. | 14 | CNMV | ||
| 15.06. | Grifols, S.A.: Grifols Launches FESILTY (fibrinogen, human-chmt) in the U.S. | 390 | GlobeNewswire (Europe) | The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.FESILTY complements... ► Artikel lesen | |
| 15.05. | Grifols SA - 6-K, Report of foreign issuer | 14 | SEC Filings | ||
| 15.05. | GRIFOLS, S.A.: Calling of the Ordinary General Shareholders' Meeting 2026 of Grifols, S.A. | 8 | CNMV |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MERCK KGAA | 143,65 | -1,03 % | Neue Folge "Börse, Baby!": Earnings-Alarm: Jetzt entscheidet sich der KI-Boom | Die KI-Euphorie bekommt erste Risse: Trotz starker Quartalszahlen geraten Tech-Aktien kräftig unter Druck. Ist das noch eine gesunde Korrektur? Die Berichtssaison zeigt derzeit, wie hoch die Erwartungen... ► Artikel lesen | |
| GSK | 22,860 | +1,06 % | Novo Nordisk, Johnson & Johnson und Co. setzen auf Plattformen - warum einzelne Medikamente für Big Pharma längst nicht mehr ausreichen | ||
| VERTEX PHARMACEUTICALS | 428,40 | -0,19 % | Vertex Pharmaceuticals Inc. Profit Climbs In Q2 | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) announced earnings for its second quarter that Increases, from the same period last yearThe company's earnings came in... ► Artikel lesen | |
| BAUSCH HEALTH | 5,300 | -1,94 % | Viking Therapeutics, BioNxt Solutions, Bausch Health - Studienerfolg entfacht neue Fantasie | Die Pharmaindustrie steht vor einer neuen Wachstumsphase. Milliarden fließen in innovative Therapien, moderne Arzneimitteltechnologien und die Weiterentwicklung etablierter Medikamente. Besonders dynamisch... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 66,00 | -0,15 % | Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis | Two global registrational Phase 3 trials initiated in ZENITH AD program
Phase 3 program based upon clinically meaningful efficacy and favorable safety data observed... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 188,15 | -0,79 % | Alnylam Pharmaceuticals: Analysten-Upgrade beflügelt Aktie nach Kurssturz | ||
| CANTOURAGE GROUP | 5,580 | 0,00 % | EQS-News: Cantourage Group SE: Cantourage begrüßt Klarstellung zum GKV-Beitragssatzstabilisierungsgesetz | EQS-News: Cantourage Group SE
/ Schlagwort(e): Marktbericht/Rechtssache
Cantourage begrüßt Klarstellung zum GKV-Beitragssatzstabilisierungsgesetz
07.08.2026 / 10:17 CET/CEST
Für... ► Artikel lesen | |
| MEDPACE | 507,40 | -0,67 % | Morning Market Movers: 707 Cayman, Zhongchao, NVE Corporation, Medpace See Big Swings | BEIJING (dpa-AFX) - At 8:25 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SCYNEXIS | 5,335 | +1,81 % | XFRA 135: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSCYNEXIS INC. DL... ► Artikel lesen | |
| INVENTIVA | 4,195 | 0,00 % | INVENTIVA: Inventiva Announces Preliminary Financial Results for the First Half of 2026 | Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026
Daix (France), New York City (New York, United States), July 30, 2026 - Inventiva (Euronext... ► Artikel lesen | |
| CHAMPIONS ONCOLOGY | 4,360 | -2,68 % | Champions Oncology, Inc.: Champions Oncology Reports Record Annual Revenue of $59 Million | Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA HACKENSACK, NJ / ACCESS Newswire / July 27, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology... ► Artikel lesen | |
| BAYER | 49,810 | +0,83 % | DAX vor spannender Woche - und Rekorden? Bayer, Siemens Energy, Commerzbank und Allianz mit ... | Ungeachtet der geopolitischen Krisenherde könnte die überwiegend positiv aufgenommene Berichtssaison der DAX-Konzern auch in der neuen Woche Rückenwind verleihen. Sinkende Ölpreise und starke Quartalszahlen... ► Artikel lesen | |
| NOVO NORDISK | 40,970 | -0,06 % | Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem | ||
| PFIZER | 23,100 | -0,15 % | Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound | ||
| BRIGHT MINDS BIOSCIENCES | 79,33 | 0,00 % | Motorola Solutions Foundation and Calculated Genius Honor Chicagoland Future Engineers With 2026 Bright Minds, Bold Futures Scholarship | NORTHAMPTON, MA / ACCESS Newswire / June 30, 2026 / Ten extraordinary Chicagoland high school seniors recently gathered at Motorola Solutions' global headquarters in Chicago, joined by family members... ► Artikel lesen |